#EULAR2024 POS0326 Multicentre cohort in Italy (N=67) showed Benralizumab and Mepolizumab 300mg (EGPA dose) exhibited a significant steroid-sparing effect, with MEPO300 demonstrating superior drug survival. MEPO100 (eosinophilic asthma dose) was numerically inferior @RheumNow